Indian firm Granules is exiting its long-standing joint venture for ibuprofen API in China against the backdrop of evolving pollution control norms and the need for growing expenditure there, while emerging supply options have reduced the need for a local JV.

The Singh brothers of Ranbaxy have been arrested over allegations of financial fraud and things appear headed further downhill. Daiichi Sankyo is also separately pursuing enforcement of damages against the brothers.

A faculty member at the Indian Institute of Technology and the founder of Indian venture ImmunoACT hopes to deliver an indigenously developed CAR-T therapy at a fraction of current treatment costs.

The global head of Dr Reddy’s biologics business unit, Raymond De Vré, discusses in an interview with Scrip how things are looking up in the US biosimilars market, why interchangeability isn’t a major concern and how galloping volume growth is being seen by the company in emerging markets.

A biopharma conference in Mumbai hears how the US biosimilars landscape could potentially change over the long term when deep price cuts set in and payers have a greater say in matters. Might big pharma consider pulling out?